Clinical trials: Unresectable Pancreatic Carcinoma
Locally Advanced or Metastatic Pancreatic Cancer
Masitinib Plus Gemcitabine in Pancreatic Cancer
The objective is to compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with locally advanced or metastatic pancreatic cancer and who have…
- Trial name
- NCT03766295
- Testing
- Masitinib, Gemcitabine
- Where
- 9 sites in Belgium, France and 6 more
- Volunteers
- 377 people
- Sponsor
- AB Science
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Neuroendocrine Tumors, Carcinoid Tumors
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who…
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Adrenal Gland Tumors, Neuroblastoma
- Trial name
- NCT00947167
- Testing
- pertuzumab, erlotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pamela L. Kunz
Pancreatic Cancer
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic…
- Trial name
- NCT01688336
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine)…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT06998940
- Testing
- Biospecimen Collection, Computed Tomography, Fluorouracil
- Where
- 274 sites in United States
- Volunteers
- 94 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Cancer
A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer
The purpose of this study is to evaluate the clinical safety and efficacy of Gemcitabine plus nab-Paclitaxel chemoradiotherapy and to determine the Maximal Tolerated Dose (MTD) for unresectable locally advanced pancreatic…
- Trial name
- NCT02272738
- Testing
- Gemcitabine, Nab-Paclitaxel
- Where
- Japan
- Volunteers
- 54 people
- Sponsor
- Osaka Medical Center for Cancer and Cardiovascular Diseases
Adenocarcinoma of the Pancreas, Pancreatic Cancer
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
This phase II trial is studying how well E7389 works as second-line therapy in treating patients with locally advanced, unresectable, or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer
- Trial name
- NCT00383760
- Testing
- eribulin mesylate
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer Non-resectable, Bile Duct Cancer
Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents
The goal of this randomized controlled trial is to compare uncovered, partially covered, and fully covered self-expandable metal stents (SEMS) in the palliative treatment of distal malignant biliary obstruction in a Swedish…
- Conditions
- Pancreatic Cancer Non-resectable, Bile Duct Cancer, Papillary Carcinoma, Duodenal Cancer
- Trial name
- NCT06453590
- Testing
- Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction., Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction., Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.
- Where
- 12 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- Region Stockholm
Pancreatic Neoplasms Malignant, Malignant Neoplasm of Gall Bladder Non-resectable
Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers
SUMMARY PROJECT TITLE: Concurrent chemo-radiation using Tomotherapy based IMRT in locally advanced Gallbladder and Pancreatic cancers: A Phase II study SPECIFIC OBJECTIVES: Primary To assess the radiological response by dose…
- Trial name
- NCT01118897
- Testing
- Tomotherapy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Hospital
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.
- Trial name
- NCT03627390
- Testing
- BP-C1, BP-C2
- Where
- Egypt
- Volunteers
- 16 people
- Sponsor
- Meabco A/S
Pancreatic Neoplasms
Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer
This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of DTA-H19 administered intratumorally in patients with unresectable, locally advanced pancreatic cancer.
- Trial name
- NCT00711997
- Testing
- DTA-H19
- Where
- 4 sites in United States, Israel
- Volunteers
- 9 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Pancreatic Cancer
HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)
The purpuse of this study is to assess toxicities of angiogenic peptide vaccine therapy with gemcitabine in treating HLA-A*0201 restricted patient with non-resectable pancreatic cancer.
- Trial name
- NCT01266720
- Testing
- VEGFR1, VEGFR2, Gemcitabine
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Fukushima Medical University
Pancreatic Cancer
Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
To determine the antitumor activity of MKC-1 in patients with unresectable or metastatic pancreatic cancer who have failed at least one prior chemotherapy regimen in either the neoadjuvant, adjuvant, or first-line metastatic…
- Trial name
- NCT00568646
- Testing
- MKC-1
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- CASI pharmaceuticals, Inc.
Pancreatic Cancer Non-resectable
A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer
This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma.
- Trial name
- NCT07898683
- Testing
- Transarterial Radioembolization
- Where
- Russia
- Volunteers
- 12 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Unresectable Locally Advanced Pancreatic Carcinoma
A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.
To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy FDA regulatory requirements.
- Trial name
- OncoPaC-1 (NCT03076216)
- Testing
- OncoSil™
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- OncoSil Medical Limited
Locally Advanced Unresectable Pancreatic Adenocarcinoma
STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Trial name
- CA209-9KH (NCT04098432)
- Testing
- Nivolumab, Stereotactic radiotherapy
- Where
- 4 sites in Czechia
- Volunteers
- 15 people
- Sponsor
- University Hospital Hradec Kralove
Pancreatic Cancer
A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.
- Trial name
- NCT02237157
- Testing
- Gemcitabine, local delivery
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- RenovoRx
Solid Tumor, Adult, Solid Tumor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- EVEREST-1 (NCT05736731)
- Testing
- A2B530, xT-Onco with HLA-LOH Assay
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- A2 Biotherapeutics Inc.
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
- Conditions
- Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
- Trial name
- NCT03138720
- Testing
- Paclitaxel Protein Bound (Abraxane)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- HonorHealth Research Institute